



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07K 14/62, A61K 38/17</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/65941</b> <b>(43) International Publication Date:</b> 23 December 1999 (23.12.99)
<p><b>(21) International Application Number:</b> PCT/GB98/01722</p> <p><b>(22) International Filing Date:</b> 12 June 1998 (12.06.98)</p> <p><b>(71) Applicants (for all designated States except US):</b> KINGS COLLEGE LONDON [GB/GB]; Strand, London WC2R 2LS (GB). DEUTSCHES WOLLFORSCHUNGSINSTITUT [DE/DE]; Veltmanplatz 8, D-5100 Aachen (DE).</p> <p><b>(72) Inventors; and</b></p> <p><b>(75) Inventors/Applicants (for US only):</b> JONES, Richard, Henry [GB/GB]; Kings College London, Strand, London WC2R 2LS (GB). BRANDENBURG, Dietrich [DE/DE]; Sudetenstrasse 63, D-64385 Reichelsheim (DE). SHO-JAEE-MORADI, Fariba [GB/GB]; Kings College London, Strand, London WC2R 2LS (GB). KLEINJUNG, Jens [DE/GB]; 27 Meadway Court, London NW11 6PN (GB).</p> <p><b>(74) Agent:</b> GILL JENNINGS &amp; EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).</p>		<p><b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b>  <i>With international search report.</i></p>
<p><b>(54) Title:</b> INSULIN ANALOGUE</p> <p><b>(57) Abstract</b></p> <p>A novel analogue of insulin has covalently conjugated thereto, preferably at the B1 residue, 3,3',5'-triiodothyroxine. The conjugate is believed to be hepatoselective, whilst it retains insulin receptor binding properties.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

INSULIN ANALOGUE

The present invention relates to novel insulin analogues which are covalent conjugates of an insulin molecule and a derivative of the hormone thyroxine, 5 3,3',5'triiodothyronine.

In WO-A-95/05187 we described novel insulin conjugates with hormones, specifically with tetraiodothyroxine (3,3',5,5'tetraiodothyronine, T4), which were hepatoselective. The hepatoselectivity was believed to be due to the fact that, when introduced percutaneously, the 10 size of the molecule (about 15% higher molecular weight than insulin itself) allows it to diffuse through the capillary endothelium into the circulation. In the circulation it is believed to bind reversibly the 15 circulating proteins having an affinity for the thyroxine moiety, namely thyroxine binding globulin, thyroxine binding prealbumin and albumin, collectively known as thyroxine binding proteins (TBP). These higher molecular weight complexes are then unable to diffuse back through capillary 20 endothelium, but are able to diffuse through the relatively larger pores of the hepatic endothelium. The conjugate is found to retain insulin activity. The hepatoselectivity ensures that insulin is directed to the site where its activity is required.

25 In WO-A-95/07931 hydrophobically modified insulin analogues are described. The insulin is generally derivatised by acylation of the pendant amino group of lysine at B29 with a fatty acid. However there is also an example of derivatising that residue with thyroxine, or 30 with tetraiodothyroacetic acid. The analogues are alleged to have a protracted profile of action, although the mechanism by which this takes place is not elucidated.

One potential problem with the T4-insulin conjugate is that it may retain thyroxine activity. The present 35 invention seeks to solve this problem while providing a conjugate which retains its hepatoselectivity, insulin activity and circulating protein affinity.

A new compound according to the invention comprises an insulin molecule covalently bound to 3,3',5'-triiodothyronine.

5 The 3,3',5'-triiodothyronine molecule is not a naturally occurring compound. It is an isomer of 3,5,3'-triiodothyronine (T3) and is consequently known as reverse T3, rT3. It has insignificant activity on thyroxine receptor, but thyroxine binding proteins have an affinity for the molecule. Thus the compound of the invention  
10 should have affinity for TBP's and, it is believed, consequential hepatoselectivity whilst the compound and its metabolites should not stimulate thyroxine activity.

The rT3 moiety should be conjugated to a residue of the insulin molecule such that insulin activity is not  
15 adversely affected. As in WO-A-95/05187, conjugation is preferably through the B1 residue of insulin. Alternatively the B29 residue may be linked to rT3. In WO-95/07931, the B29 residue may be derivatised and the methods of conjugating a carboxylic acid-containing  
20 compound to the B29 residue as disclosed in that reference may be used in the present invention.

The insulin may be made by recombinant DNA techniques or may be isolated from natural sources, human or animal. Recombinant insulin may have deleted residues as desired,  
25 for instance the B29 residue may be deleted. Other residues of naturally occurring insulin may be substituted, usually by conservative substitutions. For instance in WO-A-95/07931, analogues in which the B3 and/or A21 residues are other than those of naturally occurring insulin.

30 The rT3 molecule is conjugated to the insulin using conventional biochemical techniques in which pendant groups on the appropriate residue of the insulin molecule are covalently bonded to rT3, through the carboxylate group. The pendant group is usually the  $\epsilon$ -amino group of a lysine  
35 residue. Any other lysine residues may be rendered unreactive by protecting the  $\epsilon$ -amine groups using

conventional techniques. Protecting groups are removed after conjugation to the rT3 molecule.

The phenolic OH group of rT3 is protected during the process, also.

5        Either or both of the amine group and the carboxylate group may be activated prior to contact of the insulin with the rT3. Conventional techniques for generation of amide linkages may be used, for instance using known reagents.

10        A spacer may be included between the insulin molecule and the rT3 molecule. A spacer may, for instance, improve retention of insulin activity and/or TBP-binding. A spacer may also be used to control *in vivo* cleavage and metabolism of the conjugate compound, and consequently its insulin activity. A spacer may, for instance include a chain  
15        comprising 2 to 22 carbon and/or heteroatoms, such as a 4-10 atom chain, preferably comprising an alkylene group and carbonyl and/or amino groups, amido groups and or oxygen atoms in ester or ether linkages.

20        The inventors have found that the insulin-rT3 conjugate has a similar potency relative to human insulin itself. This is in contrast to T4-insulin, which appears to have a greater potency than human insulin. In the presence of binding proteins, especially thyroxine binding  
25        proteins, the potency of T4-insulin is reduced, whereas these proteins do not affect the potency of rT3-insulin. These data indicate that the conjugate is likely to have similar effects as insulin *in vivo*.

30        Further tests in which the ED50 of the conjugates as compared to insulin, in the presence and absence of binding proteins (human serum albumin and thyroxine binding globulin and transthyretin) show that each conjugate on its own has a similar ED50 to human insulin itself. The ED50's of the T4-insulin conjugate are significantly increased by the presence of TBG, whilst the ED50's of the rT3-insulin are  
35        not effected to a significant degree.

We have also conducted competitive binding assays of the insulin analogues compared to human insulin with

<sup>125</sup>-Insulin to insulin receptors on liver plasma membrane (LPM). Insulin is known to inhibit the binding of <sup>125</sup>-Insulin to these receptors. We have found that TBP does not affect this ability. rT3 behaves in a similar way to human insulin in that it inhibits binding of <sup>125</sup>-Insulin to the receptors on LPM and this is not affected by the presence of TBP. T4 insulin itself does inhibit <sup>125</sup>-Insulin binding to these receptors. In contrast, however, TBP significantly affects this inhibition.

The novel compound is suitable for use in a method of treatment of the human or animal, for instance to replace insulin in a method of insulin replacement therapy. The invention thus comprehends novel compositions containing the compound as well as pharmaceutical compositions containing the compound and a pharmaceutically acceptable excipient. The composition is formulated so as to be suitable for administration by the usual routes, generally by subcutaneous injection. Accordingly the carrier is generally aqueous. The invention comprehends also a new use of the compound in the manufacture of a medicament for use in a method of treatment of the human or animal body.

The following examples illustrate the invention.

25

#### Example 1

#### Preparation of [rT3(Na-B1)]-insulin

##### 1.1 Synthesis of Msc-rT3

30

50.0 mg rT3	(76.8 $\mu$ mol, 651.0 g/mol)
20.4 mg Msc-OSu	(76.9 $\mu$ mol, 265.24 g/mol)

35

50.0 mg rT3 were suspended in 400  $\mu$ l dimethylformamide and 20.4 mg Msc-OSu, dissolved in 100  $\mu$ l dimethylformamide, were added. 4  $\mu$ l of triethylamine were pipetted into the solution and the mixture was stirred overnight at room temperature.

### 1.2 Synthesis of Msc-rT3-OSu

16.6 mg DCC (80.6  $\mu\text{mol}$ , 206.3 g/mol)

16.6 md DCC were dissolved in 50  $\mu\text{l}$  dimethylformamide  
5 and added to the above reaction mixture. The activation is complete after 3 h at room temperature.

### 1.3 Synthesis of [rT3(Na-B1)]-insulin

10 230 mg A1,B29-(Msc)2-insulin (6078 g/mol, 38  $\mu\text{mol}$ ) synthesised according to Schüttler A and Brandenburg D, Hoppe-Seyler's Z. Physiol.Chem. 360, 1721-1725 (1979) were dissolved in 3 ml dimethylformamide with the addition of 4  $\mu\text{l}$  triethylamine and then reacted with 69  $\mu\text{g}$  Msc-rT3-OSu  
15 (898 g/mol, 76  $\mu\text{mol}$ , two-fold excess with respect to insulin derivative). After stirring for 3 h at room temperature the acylation was stopped by addition of 50  $\mu\text{l}$  acetic acid. The solution was dialysed overnight against distilled water and lyophilised. For cleavage of Msc  
20 protecting groups the protein material was diluted in a mixture of 1 ml dimethylformamide, 1.5 ml methanol and 1.5 ml water. The solution was cooled to 0°C and addition of 0.5 ml of ice-cold 2 M sodium hydroxide solution started the cleavage reaction. The reaction was stopped by  
25 acidification with 1 ml of 10% (v/v) acetic acid. The protein was precipitated by pipetting the reaction solution into a mixture of 250 ml of ice-cold ether and 20 ml methanol and stirring for 1 h. The ether was decanted from the precipitated protein and the protein dried in  
30 vacuo.

Purification of the raw material was performed by use of RP-MPLC. Fractions were collected and lyophilised. Chromatographic conditions:

35 Column: RP20C18, 2.5 x 250 mm, 122 ml total volume,  
Gradient: 25-40% (v/v)

2-propanol in water containing 0.1% trifluoro acetic acid, total gradient volume 1.5 l; flow rate 20 ml / 3 min.

Yield: 27 mg (10% of theory, based on A1,B29-(Msc)2-insulin)

Molecular mass: 6437 u ( calc. 6436.6 u)

Purity (RP-HPLC): 93 % (Absorption at 215 nm)

5

#### 1.4 Mass spectrometry

MS-TOF spectrometer VG ToFSpec, Fisons

Ionisation: Ar-laser, MCP Volts,: 1750, 337 nm, linear  
modus Acceleration: 20 kV

10       Standard: bovine insulin 5731 u (calc. 5731 u),  
vasointestinal peptide 1424 u (calc. 1426 u) [rT3(Na-B1)]-  
insulin: 6437 (calc. 6437)

### Example 2 - Effects of Binding Proteins on Receptor

#### 15       Binding

The rT3-insulin conjugate made in Example 1 is used in various tests to determine the binding potencies of the analogues on liver plasma membrane. <sup>125</sup>-Insulin is used as  
20       the labelled insulin. It is known that insulin itself inhibits binding of <sup>125</sup>-Insulin.

### Results

#### Equilibrium binding curves

25       The equilibrium binding curves of average normalised bound against the log-concentration of insulin or analogue (nmol/l) with or without the presence of THBP were generated. The trends initially illustrated by the curves were:

30       H-Ins, rT3-Ins and T4-Ins appear similar in their positions, i.e. there is no difference between them in their ability to inhibit the binding of <sup>125</sup>-Insulin to insulin receptors on LPM.

35       The presence of THBP does not appear to affect the ability of H-Ins to inhibit the binding of <sup>125</sup>-Insulin to insulin receptors on LPM.



The presence of THBP does not appear to affect the ability of rT3-Ins to inhibit the binding of <sup>125</sup>-Insulin to insulin receptors on LPM.

5 The presence of THBP does appear to affect the ability of T4-Ins to inhibit the binding of <sup>125</sup>-Insulin to insulin receptors on LPM as shown by the shift in the T4-Ins+THBP curves to the right. TBG seems to have the greatest effect on T4-Ins, i.e. causes the greatest shift.

#### ED50

10 The ED50's as calculated by the G-PIP software were inverse logged because the concentrations entered in G-PIP had to be entered as the log of the concentrations. The average (nmol/l)  $\pm$  SEM of the ED50's was then calculated. The results are shown in Table 1. These give a  
15 quantitative idea of the shift, if any in the equilibrium binding curves.

**TABLE 1**

Average of ED50 $\pm$ SEM			
	Average	SEM	n=
20 H-Ins	1.966	0.43	5
rT3-Ins	2.455	0.35	6
0.5% HSA	2.48	0.478	4
1% HSA	3.24	0.379	3
25 2.5% HSA	2.76		2
Transthyretin	1.805	0.55	4
0.135 $\mu$ mol/l TBG	3.147	0.35	3
T4-Ins	1.316	.034	5
0.5% HSA*	3.715		2
30 1% HSA*	5.823	2.108	3
2.5% HSA*	4.81		2
Transthyretin*	2.935	0.32	4
0.135 $\mu$ mol/l TBG*	21.67	2.258	3
0.27 $\mu$ mol/l TBG*	36.55		2

\* Fisher's test also performed.

#### Statistical analysis of the ED50's

From the statistical analysis it was found that the  
5 ED50's of rT3-Ins and T4-Ins were not significantly  
different from that of H-Ins. The ED50's of rT3-Ins with  
THBP were not significantly different from those of rT3-Ins  
without THBP present as determined by ANOVA. On the other  
hand, the ED50's of T4-Ins without THBP present ( $p < 0.05$ ) as  
10 determined by Fisher's least squares test (see Table 1\*).

#### Potency estimates

The potency estimates of the analogues relative to H-  
Ins and the analogues in the presence of THBP relative to  
15 the analogues in the absence of THBP are shown in Table 2  
with their fiducial limits. This demonstrates that rT3-Ins  
has a similar potency relative to H-Ins. T4-Ins seems to  
have a greater potency relative to H-Ins. The presence of  
THBP seems to have no effect on the binding potency  
20 estimates of rT3-Ins binding to insulin receptors relative  
to rT3-Ins without THBP present. However the presence of  
THBP present. However the presence of THBP greatly reduces  
the T4-Ins binding potency estimates relative to T4-Ins  
binding to insulin receptors without THBP present (Table  
25 2).

TABLE 2

Potency Estimates		
	Potency	95% fiducial limits
5	H-Ins	100%
	rT3-Ins	94%
	T4-Ins	184%
10	rT3-Ins	100%
	0.5% HSA	122%
	1% HSA	87%
	2.5% HSA	119%
	0.135 $\mu$ mol/l TBG	76%
	Transthyretin	183%
15	T4-Ins	100%
	0.5% HSA	27%
	1% HSA	31%
	2.5% HSA	35%
	0.135 $\mu$ mol/l TBG	5%
	Transthyretin	33%
20		

Scatchard Plots

The Scatchard plot of H-Ins demonstrates the characteristic curvilinear shape of negative co-operativity that should be exhibited by human insulin. It may be seen from the Scatchard plots of rT3-Ins and T4-Ins that these analogues also exhibit negative co-operativity due to their curvilinear shape.

Reference Example - Synthesis of Insulin - T4

The T4 insulin is B1-thyroxyl-insulin made according to the technique described in WO-A-95/05187, Example 1.

CLAIMS

1. A compound consisting of an insulin molecule covalently bound to 3,3',5' triiodothyromine.

2. A compound according to claim 1 in which the  
5 3,3',5' triiodothyromine is bound to a lysine residue of the insulin molecule.

3. A compound according to claim 2 in which the 3,3',5' triiodothyromine is bound to the B1 lysine residue.

4. A compound according to any preceding claim in  
10 which the insulin is human insulin.

5. A compound according to any preceding claim for use in a method of treatment of the human or animal body.

6. A composition comprising a compound according to any of claims 1 to 4 and a carrier.

7. A pharmaceutical composition comprising a  
15 compound according to any of claims 1 to 4 and a pharmaceutically acceptable excipient.

8. Use of a compound according to any of claims 1 to 4 in the manufacture of a composition for use in a method  
20 of treatment of the human or animal body.

9. Use according to claim 8 in which the method is insulin replacement therapy, preferably for treatment of diabetes.

## INTERNATIONAL SEARCH REPORT

Int. J. onal Application No

PCT/GB 98/01722

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K14/62 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 05187 A (UNITED MEDICAL & DENTAL SCHOOL ; DEUTSCHES WOLFFORSCHINST (DE)) 23 February 1995 cited in the application see abstract ---	1-8
A	WO 95 07931 A (NOVO NORDISK) 23 March 1995 cited in the application see abstract see examples -----	1-8



Further documents are listed in the continuation of box C



Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"S" document member of the same patent family

Date of the actual completion of the international search

2 February 1999

Date of mailing of the international search report

10/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Panzica, G

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/01722

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9505187 A	23-02-1995	EP 0725648 A	14-08-1996
		JP 10501789 T	17-02-1998
		US 5854208 A	29-12-1998
WO 9507931 A	23-03-1995	AU 4846197 A	19-02-1998
		AU 682061 B	18-09-1997
		AU 7652094 A	03-04-1995
		BG 61611 B	30-01-1998
		BG 100420 A	31-12-1996
		BR 9407508 A	07-01-1997
		CA 2171424 A	23-03-1995
		CN 1133598 A	16-10-1996
		CZ 9600789 A	16-10-1996
		EP 0792290 A	03-09-1997
		FI 961220 A	14-05-1996
		HU 75991 A	28-05-1997
		JP 9502867 T	25-03-1997
		NO 961070 A	15-05-1996
		NZ 273285 A	24-10-1997
		PL 313444 A	08-07-1996
		SK 32496 A	06-11-1996
		US 5750497 A	12-05-1998
		ZA 9407187 A	17-03-1995